Knight Therapeutics(TSE:GUD)
CA$12.06+0.01 (+0.08%)
TSE:GUD
Knight Therapeutics financials statements
CA$12.06
At close:+0.01 (+0.08%)
Want to see TSE:GUD full AI Analyst Report?
Knight Therapeutics (GUD) Income Statement
112 Followers
Knight Therapeutics Income Statement
Last quarter (Q3 2026), Knight Therapeutics's total revenue was C$137.69M, an increase of 13.28% from the same quarter last year. In Q3, Knight Therapeutics's net income was C$-2.68M. See Knight Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| C$ 450.09M | C$ 371.30M | C$ 328.20M | C$ 293.56M | C$ 243.48M | |
| C$ 150.74M | C$ 174.41M | C$ 152.65M | C$ 138.06M | C$ 115.41M | |
| C$ 152.94M | C$ 167.01M | C$ 155.54M | C$ 155.12M | C$ 128.24M | |
| Depreciation and Amortization | C$ 56.57M | C$ 53.11M | C$ 50.40M | C$ 62.62M | C$ 47.91M |
| C$ 54.37M | C$ 64.38M | C$ 40.90M | C$ 25.26M | C$ 42.59M | |
| C$ -2.20M | C$ 7.40M | C$ -2.89M | C$ -2.40M | C$ -5.32M | |
| C$ -4.50M | C$ -5.34M | C$ -19.10M | C$ -2.92M | C$ 19.52M | |
| C$ -6.70M | C$ 2.05M | C$ -21.99M | C$ -43.96M | C$ 6.69M | |
| C$ -5.37M | C$ 4.33M | C$ -16.84M | C$ -29.89M | C$ 15.68M | |
| Per Share Metrics | |||||
| Basic EPS | C$ -0.05 | C$ 0.04 | C$ -0.16 | C$ -0.26 | C$ 0.13 |
| Diluted EPS | C$ -0.05 | C$ 0.04 | C$ -0.16 | C$ -0.26 | C$ 0.13 |
| Weighted Average Shares Outstanding | 99.57M | 101.04M | 107.47M | 114.89M | 124.48M |
| Weighted Average Shares Outstanding (Diluted) | 99.57M | 101.44M | 107.47M | 114.89M | 124.52M |
Currency in CAD

